ArticleHereditas2026
miR-596 as a novel prognostic biomarker and tumor suppressor in breast cancer through targeting EIF5AL1.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn terms of global incidence and mortality, breast cancer continues to surpass all other cancers affecting women.
methodsTo explore the role of miR-596, qRT-PCR was applied to measure its expression in tissue and cell samples from 137 enrolled subjects. The regulatory interaction between miR-596 and EIF5AL1 was verified by dual-luciferase reporter assays. CCK-8 and Transwell assays were utilized to respectively measure the proliferation, migration, and invasion capabilities of the two breast cancer cell lines, MCF-7 and MDA-MB-231.
resultsA significant downregulation of miR-596 was observed in breast cancer tissues and cell lines (all P < 0.001). Clinically, reduced miR-596 expression was associated with advanced TNM stage, lymph node metastasis, and inferior overall survival (P < 0.05). EIF5AL1 was validated as a direct target gene of miR-596, and their expression levels were inversely correlated in clinical samples (r = -0.801, P < 0.001). Reintroduction of miR-596 markedly suppressed the proliferation, migration, and invasion of cancer cells, effects that were largely reversed by overexpressing EIF5AL1 (all P < 0.001).
conclusionIn breast cancer, miR-596 suppresses malignancy and predicts prognosis by targeting EIF5AL1. Thus, therapeutic modulation of this axis offers novel avenues for treatment and risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.